




RealRate

PHARMACEUTICAL 2022

Benitec Biopharma Inc
Rank 152 of 471



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Benitec Biopharma Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Benitec Biopharma Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 97% points. The greatest weakness of Benitec Biopharma Inc is the variable Net Income, reducing the Economic Capital Ratio by 39% points.

The company's Economic Capital Ratio, given in the ranking table, is 345%, being 69% points above the market average of 275%.

Input Variable	Value in 1000 USD
Assets, Current	20,608
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,369
Liabilities, Non-Current	0
Other Assets	396
Other Compr. Net Income	498
Other Expenses	123
Other Liabilities	0
Other Net Income	-286
Other Revenues	59
Property and Equipment	375
Research and Development	7,020
Selling, General and Administrative Expense	6,512

Output Variable	Value in 1000 USD
Assets	21,379
Liabilities	1,369
Expenses	13,655
Revenues	59
Stockholders Equity	20,010
Net Income	-13,882
Comprehensive Net Income	-13,633
BaseVar	18,623
ECR before Limited Liability	264%
Economic Capital Ratio	345%